<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:08:21Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8865521" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8865521</identifier>
        <datestamp>2022-02-24</datestamp>
        <setSpec>jcopo</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="case-report">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">JCO Precis Oncol</journal-id>
              <journal-id journal-id-type="iso-abbrev">JCO Precis Oncol</journal-id>
              <journal-id journal-id-type="hwp">po</journal-id>
              <journal-id journal-id-type="publisher-id">PO</journal-id>
              <journal-title-group>
                <journal-title>JCO Precision Oncology</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2473-4284</issn>
              <publisher>
                <publisher-name>Wolters Kluwer Health</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8865521</article-id>
              <article-id pub-id-type="pmcid">PMC8865521</article-id>
              <article-id pub-id-type="pmc-uid">8865521</article-id>
              <article-id pub-id-type="pmid">35138920</article-id>
              <article-id pub-id-type="pmid">35138920</article-id>
              <article-id pub-id-type="publisher-id">PO.21.00456</article-id>
              <article-id pub-id-type="doi">10.1200/PO.21.00456</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Case Reports</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Yap</surname>
                    <given-names>Timothy A.</given-names>
                  </name>
                  <degrees>MBBS, PhD, FCRP</degrees>
                  <xref rid="aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="con1" ref-type="fn"/>
                  <xref rid="cor1" ref-type="corresp"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hamilton</surname>
                    <given-names>Erika</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="con2" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bauer</surname>
                    <given-names>Todd</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="con3" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dumbrava</surname>
                    <given-names>Ecaterina E.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="con4" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jeselsohn</surname>
                    <given-names>Rinath</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="con5" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Enke</surname>
                    <given-names>Aaron</given-names>
                  </name>
                  <degrees>BS</degrees>
                  <xref rid="aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="con6" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hurley</surname>
                    <given-names>Sabrina</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="con7" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lin</surname>
                    <given-names>Kevin K.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="con8" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Habeck</surname>
                    <given-names>Jenn</given-names>
                  </name>
                  <degrees>MPH</degrees>
                  <xref rid="aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="con9" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Giordano</surname>
                    <given-names>Heidi</given-names>
                  </name>
                  <degrees>MA</degrees>
                  <xref rid="aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="con10" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Shapiro</surname>
                    <given-names>Geoffrey I.</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref rid="aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="con11" ref-type="fn"/>
                </contrib>
                <aff id="aff1"><label><sup>1</sup></label>The University of Texas MD Anderson Cancer Center, Houston, TX</aff>
                <aff id="aff2"><label><sup>2</sup></label>Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN</aff>
                <aff id="aff3"><label><sup>3</sup></label>Dana-Farber Cancer Institute, Boston, MA</aff>
                <aff id="aff4"><label><sup>4</sup></label>Clovis Oncology Inc, Boulder, CO</aff>
              </contrib-group>
              <author-notes>
                <corresp id="cor1">Timothy A. Yap, MBBS, PhD, FCRP, Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, 1400 Holcombe Blvd, Houston, TX 77030; e-mail: <email>tyap@mdanderson.org</email>.</corresp>
              </author-notes>
              <pub-date pub-type="collection">
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>9</day>
                <month>2</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>9</day>
                <month>2</month>
                <year>2022</year>
              </pub-date>
              <volume>6</volume>
              <elocation-id>e2100456</elocation-id>
              <history>
                <date date-type="received">
                  <day>15</day>
                  <month>10</month>
                  <year>2021</year>
                </date>
                <date date-type="rev-recd">
                  <day>19</day>
                  <month>11</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>13</day>
                  <month>12</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Â© 2022 by American Society of Clinical Oncology</copyright-statement>
                <copyright-year>2022</copyright-year>
                <copyright-holder>American Society of Clinical Oncology</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>Creative Commons Attribution Non-Commercial No Derivatives 4.0 License <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></license-p>
                </license>
              </permissions>
              <self-uri xlink:href="po-6-e2100456.pdf"/>
              <counts>
                <fig-count count="4"/>
                <table-count count="2"/>
                <equation-count count="0"/>
                <ref-count count="33"/>
                <page-count count="0"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>OPEN-ACCESS</meta-name>
                  <meta-value>TRUE</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="introduction">
              <title>INTRODUCTION</title>
              <p>Tumors characterized by homologous recombination deficiency, including <italic toggle="yes">BRCA1/2</italic>-mutated cancers, are sensitive to inhibition of poly(ADP-ribose) polymerases (PARPs), enzymes that regulate DNA repair.<sup><xref rid="b1" ref-type="bibr">1</xref>,<xref rid="b2" ref-type="bibr">2</xref></sup> In tumor cells with mutated homologous recombination repair (HRR) genes, PARP inhibition synergizes with homologous recombination deficiency leading to synthetic lethality because of accumulated DNA damage.<sup><xref rid="b2" ref-type="bibr">2</xref>,<xref rid="b3" ref-type="bibr">3</xref></sup></p>
              <p>Rational combinations designed to increase DNA damage and reliance on HRR are promising strategies for increasing sensitivity to PARP inhibitors, although overlapping toxicities, such as myelosuppression, suggest a need for more selective and rational targeted agents.<sup><xref rid="b2" ref-type="bibr">2</xref>,<xref rid="b4" ref-type="bibr">4</xref>-<xref rid="b6" ref-type="bibr">6</xref></sup> In human tumor cell lines, topoisomerase 1 (Topo1) inhibitors, including irinotecan and topotecan, have demonstrated synergy with PARP inhibitors.<sup><xref rid="b4" ref-type="bibr">4</xref>,<xref rid="b5" ref-type="bibr">5</xref></sup> Since PARP1 is required for the clearance of Topo1-DNA cleavable complexes, PARP inhibition may augment Topo1-mediated DNA damage or delay repair.<sup><xref rid="b7" ref-type="bibr">7</xref>,<xref rid="b8" ref-type="bibr">8</xref></sup> PARP inhibition has been shown to potentiate the cytotoxicity of SN-38, the active metabolite in irinotecan and topotecan, in mismatch repair-deficient and repair-proficient cell lines.<sup><xref rid="b9" ref-type="bibr">9</xref></sup> Furthermore, combination of a PARP inhibitor with topotecan or irinotecan in early clinical studies delayed repair of Topo1-mediated DNA damage, but also demonstrated challenges with overlapping hematologic and/or gastrointestinal toxicities.<sup><xref rid="b10" ref-type="bibr">10</xref>,<xref rid="b11" ref-type="bibr">11</xref></sup></p>
              <p>The phase Ib SEASTAR study (ClinicalTrials.gov identifier: <ext-link xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT03992131" ext-link-type="uri">NCT03992131</ext-link>) was designed to evaluate the safety, tolerability, and preliminary efficacy of the PARP inhibitor rucaparib in combination with other anticancer agents. Rucaparib is approved in the United States and European Union for treatment or maintenance treatment of patients with recurrent ovarian cancer (OC),<sup><xref rid="b12" ref-type="bibr">12</xref>,<xref rid="b13" ref-type="bibr">13</xref></sup> and in the United States for patients with metastatic castration-resistant prostate cancer,<sup><xref rid="b12" ref-type="bibr">12</xref></sup> and is under investigation in patients with solid tumors harboring mutations in HRR genes.<sup><xref rid="b14" ref-type="bibr">14</xref></sup> Arm B of the SEASTAR study investigated the combination of rucaparib with sacituzumab govitecan (SG), a conjugate of SN-38 with a humanized antibody targeting Trop-2 (trophoblast cell-surface antigen-2), a cell surface antigen overexpressed in epithelial cancers that has been linked to aggressive disease and poor prognosis. Targeted delivery of SN-38 to cancer cells through an antibody-drug conjugate (ADC) is a rational and effective strategy for combination therapy with a PARP inhibitor by potentially reducing off-target and additive toxicity.<sup><xref rid="b15" ref-type="bibr">15</xref>,<xref rid="b16" ref-type="bibr">16</xref></sup> SG is approved in the United States for the treatment of patients with metastatic triple-negative breast cancer (TNBC) and urothelial cancer (UC),<sup><xref rid="b17" ref-type="bibr">17</xref></sup> and has shown preliminary antitumor activity in other cancer types.<sup><xref rid="b18" ref-type="bibr">18</xref></sup> Here, we report the results for six patients who received the combination of rucaparib and SG in arm B of the SEASTAR study.</p>
            </sec>
            <sec sec-type="methods">
              <title>METHODS</title>
              <sec sec-type="subjects">
                <title>Study Design and Patients</title>
                <p>The phase Ib open-label, parallel-arm SEASTAR study was approved by local and/or national institutional review boards and performed in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines of the International Council for Harmonisation. All patients provided written informed consent for participation. The primary aim of the study was to determine the maximum tolerated dose and recommended phase II dose; investigator-assessed objective response rate was a key secondary end point.</p>
                <p>Arm B enrolled adult patients (â¥ 18 years) with previously treated, locally advanced or metastatic TNBC or UC; or relapsed, platinum-resistant OC. Patients with advanced, recurrent, or metastatic solid tumors with documented evidence of a deleterious alteration in <italic toggle="yes">BRCA1</italic>, <italic toggle="yes">BRCA2</italic>, <italic toggle="yes">PALB2</italic>, <italic toggle="yes">RAD51C</italic>, and/or <italic toggle="yes">RAD51D</italic> were also eligible. Genomic alterations were identified by local testing or through central next-generation sequencing of tumor tissue or baseline plasma by Foundation Medicine (Cambridge, MA). Prior PARP inhibitor treatment was allowed, but patients previously treated with irinotecan, topotecan, or any derivative were excluded. Additional inclusion and exclusion criteria are included in the Protocol.</p>
              </sec>
              <sec>
                <title>Study Treatment and Assessments</title>
                <p>This study used a standard 3 + 3 dose escalation design, with a starting dose of 300 mg rucaparib twice a day (cohort 1) or 300 mg rucaparib once daily (cohort 2) in combination with 6 mg/kg SG administered intravenously (IV), on days 1 and 8 of a 21-day cycle. Dose-limiting toxicities (DLTs) were evaluated in cycle 1. Treatment interruptions and/or dose reductions were permitted for rucaparib (in 100-mg decrements) or SG (by 25% dose reduction) in the event of toxicity. Growth factor administration was permitted for treatment of toxicity when clinically indicated. Prophylactic administration of growth factors was allowed after the DLT evaluation period. Response was assessed per RECIST, version 1.1 (v1.1). Detailed descriptions of predefined DLTs, management of adverse events (AEs), and safety and efficacy assessments are included in the Protocol.</p>
              </sec>
            </sec>
            <sec sec-type="results">
              <title>RESULTS</title>
              <p>Six patients were enrolled in two dose cohorts (n = 3 each). Patients in cohort 1 received a starting dose of 300 mg rucaparib twice a day plus 6 mg/kg IV SG on days 1 and 8 of each cycle; cohort 2 received 300 mg rucaparib once daily plus 6 mg/kg IV SG on days 1 and 8 of each cycle (Table <xref rid="tbl1" ref-type="table">1</xref>). All patients had metastatic solid tumors, including TNBC (n = 2), OC (n = 2), endometrial (n = 1), and UC (n = 1). Two patients had a known deleterious <italic toggle="yes">BRCA1</italic> or <italic toggle="yes">BRCA2</italic> gene mutation at enrollment, and one patient had a deleterious <italic toggle="yes">BARD1</italic> mutation detected in circulating tumor DNA at baseline using central plasma testing. Patients received a median of 4 prior regimens (range, 3-8), with three patients previously receiving a PARP inhibitor (Fig <xref rid="fig1" ref-type="fig">1</xref>).</p>
              <table-wrap position="float" id="tbl1">
                <label>TABLE 1.</label>
                <caption>
                  <p>Summary of Patient Demographics, Disease History, and Best Response</p>
                </caption>
                <graphic xlink:href="po-6-e2100456-g002" position="float"/>
              </table-wrap>
              <fig position="float" id="fig1" fig-type="figure">
                <label>FIG 1.</label>
                <caption>
                  <p>Overview of efficacy and treatment with rucaparib plus SG. (A) Duration of treatment and best overall response. Arrowhead denotes ongoing treatment as of the August 11, 2020, data cutoff date. (B) Change in tumor volume over time for each patient. Dotted line indicates the threshold for partial response (30% decrease from baseline). Because of the COVID-19 pandemic, SG was withheld after cycle 6 for patient 1. SG was then discontinued during cycle 11 at the patient's request. SG was withheld after cycle 4 for patient 4 because of the pandemic. <italic toggle="yes">BARD1</italic>, BRCA-associated ring domain protein 1; <italic toggle="yes">BRCA1</italic>, BRCA1 DNA repair associated; <italic toggle="yes">BRCA2</italic>, BRCA2 DNA repair associated; HRR, homologous recombination repair; OC, ovarian cancer; PARP, poly(ADP-ribose) polymerase; PD, progressive disease; PR, partial response; SD, stable disease; SG, sacituzumab govitecan; TNBC, triple-negative breast cancer; UC, urothelial cancer.</p>
                </caption>
                <graphic xlink:href="po-6-e2100456-g003" position="float"/>
              </fig>
              <p>Two of three patients in cohort 1 experienced DLTs of grade 4 neutropenia. No DLTs were observed in cohort 2, although grade 3/4 neutropenia led to 1- to 2-week delays in starting cycle 2 in all three patients. All patients experienced at least one treatment-emergent AE (TEAE) (Table <xref rid="tbl2" ref-type="table">2</xref>). The most common TEAEs were neutropenia/decreased absolute neutrophil count (ANC) (n = 6), diarrhea (n = 5), increased ALT/AST (n = 4), and asthenia/fatigue (n = 4). Grade â¥ 3 TEAEs were reported in five patients; those reported in â¥ 2 patients were neutropenia/decreased ANC (n = 5) and decreased WBC count (n = 2), all considered treatment-related. Genotypic analysis of <italic toggle="yes">ABCC2</italic>, <italic toggle="yes">SLCO1B1</italic>, and <italic toggle="yes">UGT1A1</italic><sup><xref rid="b21" ref-type="bibr">21</xref>,<xref rid="b22" ref-type="bibr">22</xref></sup> showed no clear trends relating patient genotype and toxicity (Data Supplement, Supplemental Table 1). With management of TEAEs via treatment interruption, dose reduction, and/or granulocyte colony-stimulating factor support, all patients continued treatment for â¥ 12 weeks, with a mean (Â±standard deviation) exposure of 25.7 Â± 10.5 weeks for rucaparib and 22.1 Â± 9.3 weeks (7.3 Â± 2.9 cycles) for SG (Fig <xref rid="fig2" ref-type="fig">2</xref>). As of the cutoff date of August 11, 2020, one patient with OC in cohort 1 (patient 1) remained on rucaparib for 44+ weeks (having discontinued SG after week 37 [cycle 11]).</p>
              <table-wrap position="float" id="tbl2">
                <label>TABLE 2.</label>
                <caption>
                  <p>TEAEs and Treatment-Related Adverse Events Reported in &gt; 20% of Patients (â¥ 2 patients)</p>
                </caption>
                <graphic xlink:href="po-6-e2100456-g004" position="float"/>
              </table-wrap>
              <fig position="float" id="fig2" fig-type="figure">
                <label>FIG 2.</label>
                <caption>
                  <p>Investigator-assessed tumor response and ANC over the course of treatment. A timeline is included for each patient showing treatment interruptions (gray bars) and dose reductions of oral rucaparib (twice a day or once daily) and SG (administered intravenously on days 1 and 8 of a 21-day cycle), as well as administration of growth factors. Dotted line indicates the threshold for partial response (30% decrease from baseline). ANC, absolute neutrophil count; R, rucaparib; SG, sacituzumab govitecan. <sup>a</sup>Evaluated per RECIST v1.1.</p>
                </caption>
                <graphic xlink:href="po-6-e2100456-g005" position="float"/>
              </fig>
              <p>All patients had an investigator-assessed best response of RECIST v1.1 stable disease or better (Fig <xref rid="fig1" ref-type="fig">1</xref>). Three patients had a confirmed RECIST v1.1 partial response (Fig <xref rid="fig3" ref-type="fig">3</xref>); all three patients were previously treated with a PARP inhibitor until disease progression (two with niraparib monotherapy, and one with veliparib plus dinaciclib), including one patient with no known deleterious HRR gene mutation (Table <xref rid="tbl1" ref-type="table">1</xref>). No reversion mutations in HRR genes were identified in these three patients by central testing.</p>
              <fig position="float" id="fig3" fig-type="figure">
                <label>FIG 3.</label>
                <caption>
                  <p>Representative computed tomography scans showing confirmed RECIST version 1.1 partial responses. Patient 2 had an overall 46.2% reduction in endometrial cancer tumor burden at day 88, including a 41.2% decrease in diameter of the small, left pelvic mesenteric nodule shown. Patient 4 experienced complete regression of a 1.4-cm serosal ovarian cancer metastatic implant in the posterior bladder wall by day 170. Patient 5 had a 68.6% reduction in diameter of the left iliac lymph node lesion shown here at day 86 and an overall best response of 47.1% reduction in triple-negative breast cancer tumor burden.</p>
                </caption>
                <graphic xlink:href="po-6-e2100456-g006" position="float"/>
              </fig>
            </sec>
            <sec sec-type="discussion">
              <title>DISCUSSION</title>
              <p>The results from this case series suggest that rucaparib plus SG has promising antitumor activity in patients with advanced solid tumors, including PARP inhibitorâexposed patients with tumors with and without HRR gene mutations. Although submaximal doses of SG and rucaparib were combined, decreases in ANC levels were observed. DLTs because of neutropenia were not unexpected, given the known toxicity profiles of Topo1 and PARP inhibitors.<sup><xref rid="b12" ref-type="bibr">12</xref>,<xref rid="b15" ref-type="bibr">15</xref>,<xref rid="b23" ref-type="bibr">23</xref>-<xref rid="b25" ref-type="bibr">25</xref></sup> In a previous study in advanced epithelial cancers, 33% of patients experienced grade â¥ 3 neutropenia with SG monotherapy.<sup><xref rid="b15" ref-type="bibr">15</xref></sup> Combinations of topotecan or irinotecan with olaparib or irinotecan-based chemotherapy with veliparib resulted in hematologic DLTs or severe toxicities and are no longer in development.<sup><xref rid="b26" ref-type="bibr">26</xref>-<xref rid="b28" ref-type="bibr">28</xref></sup> Although <italic toggle="yes">UGT1A1</italic> genotype has been linked to elevated rates of neutropenia and diarrhea with irinotecan or SG<sup><xref rid="b15" ref-type="bibr">15</xref>,<xref rid="b22" ref-type="bibr">22</xref>,<xref rid="b29" ref-type="bibr">29</xref>-<xref rid="b31" ref-type="bibr">31</xref></sup> and neutropenia with rucaparib plus irinotecan,<sup><xref rid="b32" ref-type="bibr">32</xref></sup> the results from this study did not show any clear relationships with such toxicities. However, correlations may have been limited by the small number of patients in this series.</p>
              <p>In patients treated with SG monotherapy, neutropenia is typically managed with a combination of treatment interruptions, dose reductions, or granulocyte colony-stimulating factor administration.<sup><xref rid="b17" ref-type="bibr">17</xref></sup> By applying similar strategies in this study, all patients were able to continue therapy and had a best response of RECIST v1.1 stable disease or better. Antitumor activity in a patient with prior PARP inhibitor treatment without HRR mutation is notable, given the current unmet clinical need in identifying rational combinations capable of enhancing the efficacy of PARP inhibitor therapy in a broader range of patients beyond those harboring HRR-mutant tumors.<sup><xref rid="b2" ref-type="bibr">2</xref>,<xref rid="b6" ref-type="bibr">6</xref></sup></p>
              <p>In summary, the results from the SEASTAR study provide proof-of-concept clinical evidence supporting further development of PARP inhibitors in combination with ADCs carrying Topo1-inhibitor payloads. Importantly, recent data suggest that a pulse-dosing schedule of rucaparib plus irinotecan allows for long-term tolerability and has demonstrated encouraging efficacy in patients with tumors harboring <italic toggle="yes">ATM</italic> mutations.<sup><xref rid="b32" ref-type="bibr">32</xref></sup> Combination of other Trop-2âdirected ADCs, such as datopotamab deruxtecan,<sup><xref rid="b18" ref-type="bibr">18</xref></sup> with more selective PARP inhibitors, such as the PARP1-targeted inhibitor AZD5305,<sup><xref rid="b33" ref-type="bibr">33</xref></sup> may also improve tolerability. Although no optimal recommended phase II dose was established in the current study, these data suggest that combination trials are warranted to investigate intermittent dosing of PARP inhibitors together with SG or other ADCs to reduce myelosuppression and optimize antitumor efficacy; future research may also help clarify the relative contributions of each agent to the observed antitumor activity.</p>
            </sec>
          </body>
          <back>
            <fn-group content-type="presented-at">
              <title>PRIOR PRESENTATION</title>
              <fn fn-type="presented-at">
                <p>Presented in part at the European Society for Medical Oncology Virtual Congress 2020, September 17, 2020.</p>
              </fn>
            </fn-group>
            <fn-group content-type="supported-by">
              <title>SUPPORT</title>
              <fn fn-type="supported-by">
                <p>Funded by Clovis Oncology Inc and was designed by the sponsor. Medical writing and editorial support were funded by Clovis Oncology and provided by Melanie Styers and Leslie Mitchell of Verascity Science. T. A. Y. is supported by MD Anderson Cancer Center Support grant (NIH/NCI P30 CA016672), the US Department of Defense Ovarian Cancer Research Program (OC200482), and the V Foundation Clinical Scholar Program (VC2020-001). T.A.Y. and E.E.D. acknowledge support from MD Anderson Cancer Center Support Grant No. NIH/NCI P30 CA016672, Clinical Translational Science Award No. 1UL1 TR003167, Cancer Prevention Research Institute of Texas Precision Oncology Decision Support Core RP150535, and Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy. G.I.S. is supported by the Dana-Farber/Harvard Cancer Center Support Grant No. (NIH/NCI P30 CA006516). T.A.Y. also acknowledges support from the US Department of Defense Ovarian Cancer Research Program (OC200482) and the V Foundation Clinical Scholar Program (VC2020-001).</p>
              </fn>
            </fn-group>
            <sec sec-type="contributed">
              <title>AUTHOR CONTRIBUTIONS</title>
              <p><bold>Conception and design:</bold> Timothy A. Yap, Erika Hamilton, Aaron Enke, Heidi Giordano, Geoffrey I. Shapiro</p>
              <p><bold>Provision of study materials or patients:</bold> Timothy A. Yap, Erika Hamilton, Todd Bauer, Ecaterina E. Dumbrava, Rinath Jeselsohn, Geoffrey I. Shapiro</p>
              <p><bold>Collection and assembly of data:</bold> Timothy A. Yap, Erika Hamilton, Todd Bauer, Ecaterina E. Dumbrava, Rinath Jeselsohn, Geoffrey I. Shapiro</p>
              <p><bold>Data analysis and interpretation:</bold> Timothy A. Yap, Erika Hamilton, Ecaterina E. Dumbrava, Aaron Enke, Kevin K. Lin, Jenn Habeck, Geoffrey I. Shapiro</p>
              <p><bold>Manuscript writing:</bold> All authors</p>
              <p><bold>Final approval of manuscript:</bold> All authors</p>
              <p><bold>Accountable for all aspects of the work:</bold> All authors</p>
            </sec>
            <sec sec-type="COI-statement">
              <title>AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST</title>
              <p>The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to <ext-link xlink:href="http://www.asco.org/rwc" ext-link-type="uri">www.asco.org/rwc</ext-link> or <ext-link xlink:href="http://ascopubs.org/po/author-center" ext-link-type="uri">ascopubs.org/po/author-center</ext-link>.</p>
              <p>Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (<ext-link xlink:href="https://openpaymentsdata.cms.gov/" ext-link-type="uri">Open Payments</ext-link>).</p>
              <fn-group content-type="conflict">
                <fn id="con1" fn-type="COI-statement">
                  <p>
                    <bold>Timothy A. Yap</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> Pfizer, EMD Serono, Clovis Oncology, Ignyta, AstraZeneca, Atrin Pharmaceuticals, Aduro Biotech, Merck, Almac Diagnostics, Bayer, Bristol Myers Squibb, Calithera Biosciences, Cybrexa Therapeutics, Janssen, Kyn Therapeutics, Roche, Seattle Genetics, Axiom Biotechnologies, F-Star, Guidepoint Global, I-Mab, Repare Therapeutics, Rubius Therapeutics, Schrodinger, Varian Medical Systems, Zai Lab</p>
                  <p><bold>Research Funding:</bold> AstraZeneca (Inst), Vertex Pharmaceuticals (Inst), Pfizer (Inst), Bayer (Inst), Tesaro (Inst), Jounce Therapeutics (Inst), Seattle Genetics (Inst), Kyowa Hakko Kirin (Inst), Constellation Pharmaceuticals (Inst), Lilly (Inst), Artios (Inst), Clovis Oncology (Inst), Cyteir (Inst), EMD Serono (Inst), Forbius (Inst), F-Star (Inst), GlaxoSmithKline (Inst), Genentech (Inst), ImmuneSensor Therapeutics (Inst), Ipsen (Inst), Karyopharm Therapeutics (Inst), Merck (Inst), Novartis (Inst), Ribon Therapeutics (Inst), Regeneron (Inst), Repare Therapeutics (Inst), Sanofi (Inst), Scholar Rock (Inst)</p>
                </fn>
                <fn id="con2" fn-type="COI-statement">
                  <p>
                    <bold>Erika Hamilton</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> Pfizer (Inst), Genentech/Roche (Inst), Lilly (Inst), Puma Biotechnology (Inst), Daiichi Sankyo (Inst), Mersana (Inst), Boehringer Ingelheim (Inst), AstraZeneca (Inst), Novartis (Inst), Silverback Therapeutics (Inst), Black Diamond Therapeutics (Inst), Nanostring (Inst), CytomX Therapeutics (Inst), Dantari (Inst), H3 Biomedicine (Inst), Merck (Inst), Seattle Genetics (Inst), Eisai (Inst), Deciphera (Inst), Arvinas (Inst), Arcus Biosciences (Inst), ITeos Therapeutics (Inst), Janssen (Inst), Loxo (Inst), Relay Therapeutics (Inst)</p>
                  <p><bold>Research Funding:</bold> AstraZeneca (Inst), Hutchison MediPharma (Inst), OncoMed (Inst), MedImmune (Inst), Stem CentRx (Inst), Genentech/Roche (Inst), Curis (Inst), Verastem (Inst), Zymeworks (Inst), Syndax (Inst), Lycera (Inst), Rgenix (Inst), Novartis (Inst), Mersana (Inst), Millennium (Inst), TapImmune Inc (Inst), Lilly (Inst), Pfizer (Inst), Tesaro (Inst), Boehringer Ingelheim (Inst), H3 Biomedicine (Inst), Radius Health (Inst), Acerta Pharma (Inst), Macrogenics (Inst), AbbVie (Inst), Immunomedics (Inst), Fujifilm (Inst), eFFECTOR Therapeutics (Inst), Merus (Inst), Nucana (Inst), Regeneron (Inst), Leap Therapeutics (Inst), Taiho Pharmaceutical (Inst), EMD Serono (Inst), Daiichi Sankyo (Inst), ArQule (Inst), Syros Pharmaceuticals (Inst), Clovis Oncology (Inst), CytomX Therapeutics (Inst), InventisBio (Inst), Deciphera (Inst), Sermonix Pharmaceuticals (Inst), Sutro Biopharma (Inst), Zenith Epigenetics (Inst), Arvinas (Inst), Harpoon (Inst), Fochon Pharmaceuticals (Inst), Black Diamond Therapeutics (Inst), Orinove (Inst), Molecular Templates (Inst), Silverback Therapeutics (Inst), Seattle Genetics (Inst), Compugen (Inst), G1 Therapeutics (Inst), Puma Biotechnology (Inst), BerGenBio (Inst), Medivation (Inst), Eisai (Inst), Takeda (Inst), Aravive (Inst), Unum Therapeutics (Inst), Torque Therapeutics (Inst), Karyopharm Therapeutics (Inst), Dana Farber Cancer Hospital (Inst), Onconova Therapeutics (Inst), Shattuck Labs (Inst), Merck (Inst), PharmaMar (Inst), Olema Pharmaceuticals (Inst), Immunogen (Inst), Plexxikon (Inst), Amgen (Inst), Akesobio (Inst), ADC Therapeutics (Inst), AtlasMedx (Inst), Aravive (Inst), Ellipses Pharma (Inst), Incyte (Inst), MabSpace Biosciences (Inst), Myriad Genetics (Inst), ORIC Pharmaceuticals (Inst), Pieris Pharmaceuticals (Inst), Pionyr (Inst), Repertoire Immune Medicines (Inst), Treadwell Therapeutics (Inst), Vincerx Pharma (Inst)</p>
                </fn>
                <fn id="con3" fn-type="COI-statement">
                  <p>
                    <bold>Todd Bauer</bold>
                  </p>
                  <p><bold>Employment:</bold> Tennessee Oncology</p>
                  <p><bold>Consulting or Advisory Role:</bold> Ignyta (Inst), Guardant Health, Loxo, Moderna Therapeutics (Inst), Pfizer (Inst), Exelixis, Blueprint Medicines, Foundation Medicine, Bayer, AstraZeneca</p>
                  <p><bold>Speakers' Bureau:</bold> Bayer, Bristol Myers Squibb, Lilly</p>
                  <p><bold>Research Funding:</bold> Daiichi Sankyo (Inst), Medpacto (Inst), Incyte (Inst), Mirati Therapeutics (Inst), MedImmune (Inst), AbbVie (Inst), AstraZeneca (Inst), Leap Therapeutics (Inst), MabVax (Inst), Stemline Therapeutics (Inst), Merck (Inst), Lilly (Inst), GlaxoSmithKline (Inst), Novartis (Inst), Pfizer (Inst), Genentech/Roche (Inst), Deciphera (Inst), Merrimack (Inst), Immunogen (Inst), Millennium (Inst), Ignyta (Inst), Calithera Biosciences (Inst), Kolltan Pharmaceuticals (Inst), Principa Biopharma (Inst), Peleton (Inst), Immunocore (Inst), Roche (Inst), Aileron Therapeutics (Inst), Bristol Myers Squibb (Inst), Amgen (Inst), Moderna Therapeutics (Inst), Sanofi (Inst), Boehringer Ingelheim (Inst), Astellas Pharma (Inst), Five Prime Therapeutics (Inst), Jacobio (Inst), Top Alliance BioScience (Inst), Loxo (Inst), Janssen (Inst), Clovis Oncology (Inst), Takeda (Inst), Karyopharm Therapeutics (Inst), Onyx (Inst), Phosplatin Therapeutics (Inst), Foundation Medicine (Inst), ARMO BioSciences (Inst)</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Astellas Pharma, AstraZeneca, Celgene, Clovis Oncology, EMD Serono, Genentech, Lilly, Merck, Novartis, Pharmacyclics, Sysmex, Pfizer</p>
                </fn>
                <fn id="con4" fn-type="COI-statement">
                  <p>
                    <bold>Ecaterina E. Dumbrava</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> Bolt Biotherapeutics, Catamaran Bio</p>
                  <p><bold>Research Funding:</bold> Bayer (Inst), Immunocore (Inst), Amgen (Inst), NCI (Inst), Aileron Therapeutics (Inst), Compugen (Inst), TRACON Pharma (Inst), Unum Therapeutics (Inst), Immunomedics (Inst), Bolt Biotherapeutics (Inst), Aprea Therapeutics (Inst), Bellicum Pharmaceuticals (Inst), PMV Pharma (Inst), Triumvira Immunologics Inc (Inst), Seattle Genetics (Inst), Mereo BioPharma 5 Inc (Inst), Sanofi (Inst), Astex Therapetics (Inst)</p>
                </fn>
                <fn id="con5" fn-type="COI-statement">
                  <p>
                    <bold>Rinath Jeseslsohn</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> Luminex, Carrick Therapeutics</p>
                  <p><bold>Research Funding:</bold> Lilly, Pfizer</p>
                </fn>
                <fn id="con6" fn-type="COI-statement">
                  <p>
                    <bold>Aaron Enke</bold>
                  </p>
                  <p><bold>Employment:</bold> Clovis Oncology</p>
                  <p><bold>Stock and Other Ownership Interests:</bold> Clovis Oncology</p>
                </fn>
                <fn id="con7" fn-type="COI-statement">
                  <p>
                    <bold>Sabrina Hurley</bold>
                  </p>
                  <p><bold>Employment:</bold> Clovis Oncology</p>
                  <p><bold>Stock and Other Ownership Interests:</bold> Clovis Oncology, Pfizer</p>
                </fn>
                <fn id="con8" fn-type="COI-statement">
                  <p>
                    <bold>Kevin K. Lin</bold>
                  </p>
                  <p><bold>Employment:</bold> Clovis Oncology</p>
                  <p><bold>Stock and Other Ownership Interests:</bold> Clovis Oncology</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Clovis Oncology</p>
                </fn>
                <fn id="con9" fn-type="COI-statement">
                  <p>
                    <bold>Jenn Habeck</bold>
                  </p>
                  <p><bold>Employment:</bold> Clovis Oncology</p>
                  <p><bold>Stock and Other Ownership Interests:</bold> Clovis Oncology</p>
                </fn>
                <fn id="con10" fn-type="COI-statement">
                  <p>
                    <bold>Heidi Giordano</bold>
                  </p>
                  <p><bold>Employment:</bold> Clovis Oncology</p>
                  <p><bold>Stock and Other Ownership Interests:</bold> Clovis Oncology</p>
                </fn>
                <fn id="con11" fn-type="COI-statement">
                  <p>
                    <bold>Geoffrey I. Shapiro</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> G1 Therapeutics, Lilly, Pfizer, Roche, Merck Serono, Sierra Oncology, Cybrexa Therapeutics, Ipsen, Bayer, Fusion Pharmaceuticals, Bicycle Therapeutics, Almac Diagnostics, Astex Pharmaceuticals, Daiichi Sankyo, Angiex, Seattle Genetics, Artios, Boehringer Ingelheim, Concarlo, Atrin Pharmaceuticals, Syros Pharmaceuticals, Zentalis, CytomX Therapeutics, Blueprint Medicines, Kymera, ImmunoMet Therapeutics, Asana</p>
                  <p><bold>Research Funding:</bold> Pfizer (Inst), Genentech (Inst), Bayer (Inst), Immune Design (Inst), Vertex (Inst), Millennium (Inst), Puma Biotechnology (Inst), Tensha Therapeutics (Inst), Covidien (Inst), Novartis (Inst), Cellceutix (Inst), Sanofi (Inst), Cyclacel (Inst), Mirati Therapeutics (Inst), AstraZeneca (Inst), GlaxoSmithKline (Inst), Lilly (Inst), Aileron Therapeutics (Inst), PharmaMar (Inst), PTC Therapeutics (Inst), Roche (Inst), CanBas (Inst), Tesaro (Inst), Merck Serono (Inst), Sierra Oncology (Inst), Syros Pharmaceuticals (Inst), Curis (Inst), Merck (Inst), Array BioPharma (Inst), Seattle Genetics (Inst), Clovis Oncology (Inst), Exelixis (Inst), Boehringer Ingelheim (Inst), Esperas Pharma (Inst), Amgen (Inst), Bristol Myers Squibb (Inst), AstraZeneca (Inst)</p>
                  <p><bold>Patents, Royalties, Other Intellectual Property:</bold> Patent No.: 9872874, Title: Dosage regimen for sapacitabine and seliciclib Issue Date: January 23, 2018, Provisional Patent No.: 62/538,319, Title: Compositions and methods for predicting response and resistance to CDK4/6 inhibition, Filed: July 28, 2017</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Lilly, Pfizer, Bicycle Therapeutics, G1 Therapeutics, Sierra Oncology, Bayer</p>
                  <p>No other potential conflicts of interest were reported.</p>
                </fn>
              </fn-group>
            </sec>
            <notes>
              <fn-group content-type="conflict">
                <fn fn-type="COI-statement">
                  <p>
                    <bold>Timothy A. Yap</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> Pfizer, EMD Serono, Clovis Oncology, Ignyta, AstraZeneca, Atrin Pharmaceuticals, Aduro Biotech, Merck, Almac Diagnostics, Bayer, Bristol Myers Squibb, Calithera Biosciences, Cybrexa Therapeutics, Janssen, Kyn Therapeutics, Roche, Seattle Genetics, Axiom Biotechnologies, F-Star, Guidepoint Global, I-Mab, Repare Therapeutics, Rubius Therapeutics, Schrodinger, Varian Medical Systems, Zai Lab</p>
                  <p><bold>Research Funding:</bold> AstraZeneca (Inst), Vertex Pharmaceuticals (Inst), Pfizer (Inst), Bayer (Inst), Tesaro (Inst), Jounce Therapeutics (Inst), Seattle Genetics (Inst), Kyowa Hakko Kirin (Inst), Constellation Pharmaceuticals (Inst), Lilly (Inst), Artios (Inst), Clovis Oncology (Inst), Cyteir (Inst), EMD Serono (Inst), Forbius (Inst), F-Star (Inst), GlaxoSmithKline (Inst), Genentech (Inst), ImmuneSensor Therapeutics (Inst), Ipsen (Inst), Karyopharm Therapeutics (Inst), Merck (Inst), Novartis (Inst), Ribon Therapeutics (Inst), Regeneron (Inst), Repare Therapeutics (Inst), Sanofi (Inst), Scholar Rock (Inst)</p>
                </fn>
                <fn fn-type="COI-statement">
                  <p>
                    <bold>Erika Hamilton</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> Pfizer (Inst), Genentech/Roche (Inst), Lilly (Inst), Puma Biotechnology (Inst), Daiichi Sankyo (Inst), Mersana (Inst), Boehringer Ingelheim (Inst), AstraZeneca (Inst), Novartis (Inst), Silverback Therapeutics (Inst), Black Diamond Therapeutics (Inst), Nanostring (Inst), CytomX Therapeutics (Inst), Dantari (Inst), H3 Biomedicine (Inst), Merck (Inst), Seattle Genetics (Inst), Eisai (Inst), Deciphera (Inst), Arvinas (Inst), Arcus Biosciences (Inst), ITeos Therapeutics (Inst), Janssen (Inst), Loxo (Inst), Relay Therapeutics (Inst)</p>
                  <p><bold>Research Funding:</bold> AstraZeneca (Inst), Hutchison MediPharma (Inst), OncoMed (Inst), MedImmune (Inst), Stem CentRx (Inst), Genentech/Roche (Inst), Curis (Inst), Verastem (Inst), Zymeworks (Inst), Syndax (Inst), Lycera (Inst), Rgenix (Inst), Novartis (Inst), Mersana (Inst), Millennium (Inst), TapImmune Inc (Inst), Lilly (Inst), Pfizer (Inst), Tesaro (Inst), Boehringer Ingelheim (Inst), H3 Biomedicine (Inst), Radius Health (Inst), Acerta Pharma (Inst), Macrogenics (Inst), AbbVie (Inst), Immunomedics (Inst), Fujifilm (Inst), eFFECTOR Therapeutics (Inst), Merus (Inst), Nucana (Inst), Regeneron (Inst), Leap Therapeutics (Inst), Taiho Pharmaceutical (Inst), EMD Serono (Inst), Daiichi Sankyo (Inst), ArQule (Inst), Syros Pharmaceuticals (Inst), Clovis Oncology (Inst), CytomX Therapeutics (Inst), InventisBio (Inst), Deciphera (Inst), Sermonix Pharmaceuticals (Inst), Sutro Biopharma (Inst), Zenith Epigenetics (Inst), Arvinas (Inst), Harpoon (Inst), Fochon Pharmaceuticals (Inst), Black Diamond Therapeutics (Inst), Orinove (Inst), Molecular Templates (Inst), Silverback Therapeutics (Inst), Seattle Genetics (Inst), Compugen (Inst), G1 Therapeutics (Inst), Puma Biotechnology (Inst), BerGenBio (Inst), Medivation (Inst), Eisai (Inst), Takeda (Inst), Aravive (Inst), Unum Therapeutics (Inst), Torque Therapeutics (Inst), Karyopharm Therapeutics (Inst), Dana Farber Cancer Hospital (Inst), Onconova Therapeutics (Inst), Shattuck Labs (Inst), Merck (Inst), PharmaMar (Inst), Olema Pharmaceuticals (Inst), Immunogen (Inst), Plexxikon (Inst), Amgen (Inst), Akesobio (Inst), ADC Therapeutics (Inst), AtlasMedx (Inst), Aravive (Inst), Ellipses Pharma (Inst), Incyte (Inst), MabSpace Biosciences (Inst), Myriad Genetics (Inst), ORIC Pharmaceuticals (Inst), Pieris Pharmaceuticals (Inst), Pionyr (Inst), Repertoire Immune Medicines (Inst), Treadwell Therapeutics (Inst), Vincerx Pharma (Inst)</p>
                </fn>
                <fn fn-type="COI-statement">
                  <p>
                    <bold>Todd Bauer</bold>
                  </p>
                  <p><bold>Employment:</bold> Tennessee Oncology</p>
                  <p><bold>Consulting or Advisory Role:</bold> Ignyta (Inst), Guardant Health, Loxo, Moderna Therapeutics (Inst), Pfizer (Inst), Exelixis, Blueprint Medicines, Foundation Medicine, Bayer, AstraZeneca</p>
                  <p><bold>Speakers' Bureau:</bold> Bayer, Bristol Myers Squibb, Lilly</p>
                  <p><bold>Research Funding:</bold> Daiichi Sankyo (Inst), Medpacto (Inst), Incyte (Inst), Mirati Therapeutics (Inst), MedImmune (Inst), AbbVie (Inst), AstraZeneca (Inst), Leap Therapeutics (Inst), MabVax (Inst), Stemline Therapeutics (Inst), Merck (Inst), Lilly (Inst), GlaxoSmithKline (Inst), Novartis (Inst), Pfizer (Inst), Genentech/Roche (Inst), Deciphera (Inst), Merrimack (Inst), Immunogen (Inst), Millennium (Inst), Ignyta (Inst), Calithera Biosciences (Inst), Kolltan Pharmaceuticals (Inst), Principa Biopharma (Inst), Peleton (Inst), Immunocore (Inst), Roche (Inst), Aileron Therapeutics (Inst), Bristol Myers Squibb (Inst), Amgen (Inst), Moderna Therapeutics (Inst), Sanofi (Inst), Boehringer Ingelheim (Inst), Astellas Pharma (Inst), Five Prime Therapeutics (Inst), Jacobio (Inst), Top Alliance BioScience (Inst), Loxo (Inst), Janssen (Inst), Clovis Oncology (Inst), Takeda (Inst), Karyopharm Therapeutics (Inst), Onyx (Inst), Phosplatin Therapeutics (Inst), Foundation Medicine (Inst), ARMO BioSciences (Inst)</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Astellas Pharma, AstraZeneca, Celgene, Clovis Oncology, EMD Serono, Genentech, Lilly, Merck, Novartis, Pharmacyclics, Sysmex, Pfizer</p>
                </fn>
                <fn fn-type="COI-statement">
                  <p>
                    <bold>Ecaterina E. Dumbrava</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> Bolt Biotherapeutics, Catamaran Bio</p>
                  <p><bold>Research Funding:</bold> Bayer (Inst), Immunocore (Inst), Amgen (Inst), NCI (Inst), Aileron Therapeutics (Inst), Compugen (Inst), TRACON Pharma (Inst), Unum Therapeutics (Inst), Immunomedics (Inst), Bolt Biotherapeutics (Inst), Aprea Therapeutics (Inst), Bellicum Pharmaceuticals (Inst), PMV Pharma (Inst), Triumvira Immunologics Inc (Inst), Seattle Genetics (Inst), Mereo BioPharma 5 Inc (Inst), Sanofi (Inst), Astex Therapetics (Inst)</p>
                </fn>
                <fn fn-type="COI-statement">
                  <p>
                    <bold>Rinath Jeseslsohn</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> Luminex, Carrick Therapeutics</p>
                  <p><bold>Research Funding:</bold> Lilly, Pfizer</p>
                </fn>
                <fn fn-type="COI-statement">
                  <p>
                    <bold>Aaron Enke</bold>
                  </p>
                  <p><bold>Employment:</bold> Clovis Oncology</p>
                  <p><bold>Stock and Other Ownership Interests:</bold> Clovis Oncology</p>
                </fn>
                <fn fn-type="COI-statement">
                  <p>
                    <bold>Sabrina Hurley</bold>
                  </p>
                  <p><bold>Employment:</bold> Clovis Oncology</p>
                  <p><bold>Stock and Other Ownership Interests:</bold> Clovis Oncology, Pfizer</p>
                </fn>
                <fn fn-type="COI-statement">
                  <p>
                    <bold>Kevin K. Lin</bold>
                  </p>
                  <p><bold>Employment:</bold> Clovis Oncology</p>
                  <p><bold>Stock and Other Ownership Interests:</bold> Clovis Oncology</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Clovis Oncology</p>
                </fn>
                <fn fn-type="COI-statement">
                  <p>
                    <bold>Jenn Habeck</bold>
                  </p>
                  <p><bold>Employment:</bold> Clovis Oncology</p>
                  <p><bold>Stock and Other Ownership Interests:</bold> Clovis Oncology</p>
                </fn>
                <fn fn-type="COI-statement">
                  <p>
                    <bold>Heidi Giordano</bold>
                  </p>
                  <p><bold>Employment:</bold> Clovis Oncology</p>
                  <p><bold>Stock and Other Ownership Interests:</bold> Clovis Oncology</p>
                </fn>
                <fn fn-type="COI-statement">
                  <p>
                    <bold>Geoffrey I. Shapiro</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> G1 Therapeutics, Lilly, Pfizer, Roche, Merck Serono, Sierra Oncology, Cybrexa Therapeutics, Ipsen, Bayer, Fusion Pharmaceuticals, Bicycle Therapeutics, Almac Diagnostics, Astex Pharmaceuticals, Daiichi Sankyo, Angiex, Seattle Genetics, Artios, Boehringer Ingelheim, Concarlo, Atrin Pharmaceuticals, Syros Pharmaceuticals, Zentalis, CytomX Therapeutics, Blueprint Medicines, Kymera, ImmunoMet Therapeutics, Asana</p>
                  <p><bold>Research Funding:</bold> Pfizer (Inst), Genentech (Inst), Bayer (Inst), Immune Design (Inst), Vertex (Inst), Millennium (Inst), Puma Biotechnology (Inst), Tensha Therapeutics (Inst), Covidien (Inst), Novartis (Inst), Cellceutix (Inst), Sanofi (Inst), Cyclacel (Inst), Mirati Therapeutics (Inst), AstraZeneca (Inst), GlaxoSmithKline (Inst), Lilly (Inst), Aileron Therapeutics (Inst), PharmaMar (Inst), PTC Therapeutics (Inst), Roche (Inst), CanBas (Inst), Tesaro (Inst), Merck Serono (Inst), Sierra Oncology (Inst), Syros Pharmaceuticals (Inst), Curis (Inst), Merck (Inst), Array BioPharma (Inst), Seattle Genetics (Inst), Clovis Oncology (Inst), Exelixis (Inst), Boehringer Ingelheim (Inst), Esperas Pharma (Inst), Amgen (Inst), Bristol Myers Squibb (Inst), AstraZeneca (Inst)</p>
                  <p><bold>Patents, Royalties, Other Intellectual Property:</bold> Patent No.: 9872874, Title: Dosage regimen for sapacitabine and seliciclib Issue Date: January 23, 2018, Provisional Patent No.: 62/538,319, Title: Compositions and methods for predicting response and resistance to CDK4/6 inhibition, Filed: July 28, 2017</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Lilly, Pfizer, Bicycle Therapeutics, G1 Therapeutics, Sierra Oncology, Bayer</p>
                  <p>No other potential conflicts of interest were reported.</p>
                </fn>
              </fn-group>
            </notes>
            <ref-list>
              <title>REFERENCES</title>
              <ref id="b1">
                <label>1.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>AmÃ©</surname><given-names>JC</given-names></name><name><surname>Spenlehauer</surname><given-names>C</given-names></name><name><surname>De Murcia</surname><given-names>G</given-names></name></person-group><article-title>The PARP superfamily</article-title><source>BioEssays</source><volume>26</volume><fpage>882</fpage>â<lpage>893</lpage><year>2004</year><pub-id pub-id-type="pmid">15273990</pub-id></mixed-citation>
              </ref>
              <ref id="b2">
                <label>2.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rose</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Burgess</surname>
                      <given-names>JT</given-names>
                    </name>
                    <name>
                      <surname>O'Byrne</surname>
                      <given-names>K</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>PARP inhibitors: Clinical relevance, mechanisms of action and tumor resistance</article-title>
                  <source>Front Cell Dev Biol</source>
                  <volume>8</volume>
                  <fpage>564601</fpage>
                  <year>2020</year>
                  <pub-id pub-id-type="pmid">33015058</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b3">
                <label>3.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashworth</surname><given-names>A</given-names></name></person-group><article-title>A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair</article-title><source>J Clin Oncol</source><volume>26</volume><fpage>3785</fpage>â<lpage>3790</lpage><year>2008</year><pub-id pub-id-type="pmid">18591545</pub-id></mixed-citation>
              </ref>
              <ref id="b4">
                <label>4.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delaney</surname><given-names>CA</given-names></name><name><surname>Wang</surname><given-names>LZ</given-names></name><name><surname>Kyle</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines</article-title><source>Clin Cancer Res</source><volume>6</volume><fpage>2860</fpage>â<lpage>2867</lpage><year>2000</year><pub-id pub-id-type="pmid">10914735</pub-id></mixed-citation>
              </ref>
              <ref id="b5">
                <label>5.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murai</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Morris</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition</article-title><source>J Pharmacol Exp Ther</source><volume>349</volume><fpage>408</fpage>â<lpage>416</lpage><year>2014</year><pub-id pub-id-type="pmid">24650937</pub-id></mixed-citation>
              </ref>
              <ref id="b6">
                <label>6.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>PiliÃ©</surname><given-names>PG</given-names></name><name><surname>Gay</surname><given-names>CM</given-names></name><name><surname>Byers</surname><given-names>LA</given-names></name><etal>et al</etal></person-group><article-title>PARP inhibitors: Extending benefit beyond BRCA-mutant cancers</article-title><source>Clin Cancer Res</source><volume>25</volume><fpage>3759</fpage>â<lpage>3771</lpage><year>2019</year><pub-id pub-id-type="pmid">30760478</pub-id></mixed-citation>
              </ref>
              <ref id="b7">
                <label>7.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>LM</given-names></name><name><surname>Willmore</surname><given-names>E</given-names></name><name><surname>Austin</surname><given-names>CA</given-names></name><etal>et al</etal></person-group><article-title>The novel poly(ADP-ribose) polymerase inhibitor, AG14361 sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks</article-title><source>Clin Cancer Res</source><volume>11</volume><fpage>8449</fpage>â<lpage>8457</lpage><year>2005</year><pub-id pub-id-type="pmid">16322308</pub-id></mixed-citation>
              </ref>
              <ref id="b8">
                <label>8.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Znojek</surname><given-names>P</given-names></name><name><surname>Willmore</surname><given-names>E</given-names></name><name><surname>Curtin</surname><given-names>NJ</given-names></name></person-group><article-title>Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase</article-title><source>Br J Cancer</source><volume>111</volume><fpage>1319</fpage>â<lpage>1326</lpage><year>2014</year><pub-id pub-id-type="pmid">25003660</pub-id></mixed-citation>
              </ref>
              <ref id="b9">
                <label>9.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tahara</surname><given-names>M</given-names></name><name><surname>Inoue</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>F</given-names></name><etal>et al</etal></person-group><article-title>The use of olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of rad51-mediated repair of DNA double-strand breaks</article-title><source>Mol Cancer Ther</source><volume>13</volume><fpage>1170</fpage>â<lpage>1180</lpage><year>2014</year><pub-id pub-id-type="pmid">24577941</pub-id></mixed-citation>
              </ref>
              <ref id="b10">
                <label>10.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LoRusso</surname><given-names>PM</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Burger</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Phase I safety, pharmacokinetic, and pharmacodynamic study of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with irinotecan in patients with advanced solid tumors</article-title><source>Clin Cancer Res</source><volume>22</volume><fpage>3227</fpage>â<lpage>3237</lpage><year>2016</year><pub-id pub-id-type="pmid">26842236</pub-id></mixed-citation>
              </ref>
              <ref id="b11">
                <label>11.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kummar</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>A</given-names></name><name><surname>Ji</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas</article-title><source>Cancer Res</source><volume>71</volume><fpage>5626</fpage>â<lpage>5634</lpage><year>2011</year><pub-id pub-id-type="pmid">21795476</pub-id></mixed-citation>
              </ref>
              <ref id="b12">
                <label>12.</label>
                <mixed-citation publication-type="book">
                  <source>Rubraca (Rucaparib) Tablets [prescribing information]</source>
                  <publisher-loc>Boulder, CO</publisher-loc>
                  <publisher-name>Clovis Oncology</publisher-name>
                  <year>2020</year>
                  <ext-link xlink:href="https://clovisoncology.com/pdfs/RubracaUSPI.pdf" ext-link-type="uri">https://clovisoncology.com/pdfs/RubracaUSPI.pdf</ext-link>
                </mixed-citation>
              </ref>
              <ref id="b13">
                <label>13.</label>
                <mixed-citation publication-type="book">
                  <source>Rubraca (Rucaparib) Tablets [summary of product characteristics]</source>
                  <publisher-loc>Swords, Ireland</publisher-loc>
                  <publisher-name>Clovis Oncology Ireland</publisher-name>
                  <year>2019</year>
                  <ext-link xlink:href="https://www.ema.europa.eu/en/documents/product-information/rubraca-epar-product-information_en.pdf" ext-link-type="uri">https://www.ema.europa.eu/en/documents/product-information/rubraca-epar-product-information_en.pdf</ext-link>
                </mixed-citation>
              </ref>
              <ref id="b14">
                <label>14.</label>
                <mixed-citation publication-type="webpage">
                  <person-group person-group-type="author">
                    <collab>ClinicalTrials.gov</collab>
                  </person-group>
                  <article-title>A study to evaluate rucaparib in patients with solid tumors and with deleterious mutations in HRR genes (LODESTAR)</article-title>
                  <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT04171700" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT04171700</ext-link>
                </mixed-citation>
              </ref>
              <ref id="b15">
                <label>15.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ocean</surname><given-names>AJ</given-names></name><name><surname>Starodub</surname><given-names>AN</given-names></name><name><surname>Bardia</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics</article-title><source>Cancer</source><volume>123</volume><fpage>3843</fpage>â<lpage>3854</lpage><year>2017</year><pub-id pub-id-type="pmid">28558150</pub-id></mixed-citation>
              </ref>
              <ref id="b16">
                <label>16.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stepan</surname><given-names>LP</given-names></name><name><surname>Trueblood</surname><given-names>ES</given-names></name><name><surname>Hale</surname><given-names>K</given-names></name><etal>et al</etal></person-group><article-title>Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: Potential implications as a cancer therapeutic target</article-title><source>J Histochem Cytochem</source><volume>59</volume><fpage>701</fpage>â<lpage>710</lpage><year>2011</year><pub-id pub-id-type="pmid">21551320</pub-id></mixed-citation>
              </ref>
              <ref id="b17">
                <label>17.</label>
                <mixed-citation publication-type="book">
                  <source>Trodelvy (Sacituzumab Govitecan-Hziy) Injection [prescribing information]</source>
                  <publisher-loc>Morris Plains, NJ</publisher-loc>
                  <publisher-name>Immunomedics</publisher-name>
                  <year>2021</year>
                  <ext-link xlink:href="https://www.gilead.com/-/media/files/pdfs/medicines/oncology/trodelvy/trodelvy_pi.pdf" ext-link-type="uri">https://www.gilead.com/-/media/files/pdfs/medicines/oncology/trodelvy/trodelvy_pi.pdf</ext-link>
                </mixed-citation>
              </ref>
              <ref id="b18">
                <label>18.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bardia</surname><given-names>A</given-names></name></person-group><article-title>Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for triple-negative breast cancer (TNBC): Preliminary results from an ongoing phase 1 trial</article-title><source>Ann Oncol</source><volume>32</volume><fpage>S60</fpage>â<lpage>S78</lpage><year>2021</year><issue>suppl 2</issue></mixed-citation>
              </ref>
              <ref id="b19">
                <label>19.</label>
                <mixed-citation publication-type="webpage">
                  <article-title>ClinVar database: <italic toggle="yes">BRCA1</italic> N1355fs*10</article-title>
                  <ext-link xlink:href="https://www.ncbi.nlm.nih.gov/clinvar/variation/17674/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/clinvar/variation/17674/</ext-link>
                </mixed-citation>
              </ref>
              <ref id="b20">
                <label>20.</label>
                <mixed-citation publication-type="webpage">
                  <article-title>ClinVar database: <italic toggle="yes">BRCA2</italic> E2846fs*22</article-title>
                  <ext-link xlink:href="https://www.ncbi.nlm.nih.gov/clinvar/variation/52614/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/clinvar/variation/52614/</ext-link>
                </mixed-citation>
              </ref>
              <ref id="b21">
                <label>21.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhodes</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><etal>et al</etal></person-group><article-title>ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer treated with first-line irinotecan</article-title><source>Drug Metab Lett</source><volume>1</volume><fpage>23</fpage>â<lpage>30</lpage><year>2008</year></mixed-citation>
              </ref>
              <ref id="b22">
                <label>22.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Innocenti</surname><given-names>F</given-names></name><name><surname>Kroetz</surname><given-names>DL</given-names></name><name><surname>Schuetz</surname><given-names>E</given-names></name><etal>et al</etal></person-group><article-title>Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics</article-title><source>J Clin Oncol</source><volume>27</volume><fpage>2604</fpage>â<lpage>2614</lpage><year>2009</year><pub-id pub-id-type="pmid">19349540</pub-id></mixed-citation>
              </ref>
              <ref id="b23">
                <label>23.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seiter</surname><given-names>K</given-names></name></person-group><article-title>Toxicity of the topoisomerase I inhibitors</article-title><source>Expert Opin Drug Saf</source><volume>4</volume><fpage>45</fpage>â<lpage>53</lpage><year>2005</year><pub-id pub-id-type="pmid">15709897</pub-id></mixed-citation>
              </ref>
              <ref id="b24">
                <label>24.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shitara</surname><given-names>K</given-names></name><name><surname>Bang</surname><given-names>Y-J</given-names></name><name><surname>Iwasa</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer</article-title><source>N Engl J Med</source><volume>382</volume><fpage>2419</fpage>â<lpage>2430</lpage><year>2020</year><pub-id pub-id-type="pmid">32469182</pub-id></mixed-citation>
              </ref>
              <ref id="b25">
                <label>25.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Modi</surname><given-names>S</given-names></name><name><surname>Saura</surname><given-names>C</given-names></name><name><surname>Yamashita</surname><given-names>T</given-names></name><etal>et al</etal></person-group><article-title>Trastuzumab deruxtecan in previously treated HER2-positive breast cancer</article-title><source>N Engl J Med</source><volume>382</volume><fpage>610</fpage>â<lpage>621</lpage><year>2020</year><pub-id pub-id-type="pmid">31825192</pub-id></mixed-citation>
              </ref>
              <ref id="b26">
                <label>26.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samol</surname><given-names>J</given-names></name><name><surname>Ranson</surname><given-names>M</given-names></name><name><surname>Scott</surname><given-names>E</given-names></name><etal>et al</etal></person-group><article-title>Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: A phase I study</article-title><source>Invest New Drugs</source><volume>30</volume><fpage>1493</fpage>â<lpage>1500</lpage><year>2012</year><pub-id pub-id-type="pmid">21590367</pub-id></mixed-citation>
              </ref>
              <ref id="b27">
                <label>27.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>EX</given-names></name><name><surname>Jonker</surname><given-names>DJ</given-names></name><name><surname>Siu</surname><given-names>LL</given-names></name><etal>et al</etal></person-group><article-title>A phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187</article-title><source>Invest New Drugs</source><volume>34</volume><fpage>450</fpage>â<lpage>457</lpage><year>2016</year><pub-id pub-id-type="pmid">27075016</pub-id></mixed-citation>
              </ref>
              <ref id="b28">
                <label>28.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiorean</surname><given-names>EG</given-names></name><name><surname>Guthrie</surname><given-names>KA</given-names></name><name><surname>Philip</surname><given-names>PA</given-names></name><etal>et al</etal></person-group><article-title>Randomized phase II study of PARP inhibitor veliparib with modified FOLFIRI versus FOLFIRI as second line treatment of metastatic pancreatic cancer: SWOG S1513</article-title><source>Clin Cancer Res</source><volume>27</volume><fpage>6314</fpage>â<lpage>6322</lpage><year>2021</year><pub-id pub-id-type="pmid">34580114</pub-id></mixed-citation>
              </ref>
              <ref id="b29">
                <label>29.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Innocenti</surname><given-names>F</given-names></name><name><surname>Undevia</surname><given-names>SD</given-names></name><name><surname>Iyer</surname><given-names>L</given-names></name><etal>et al</etal></person-group><article-title>Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan</article-title><source>J Clin Oncol</source><volume>22</volume><fpage>1382</fpage>â<lpage>1388</lpage><year>2004</year><pub-id pub-id-type="pmid">15007088</pub-id></mixed-citation>
              </ref>
              <ref id="b30">
                <label>30.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>D</given-names></name><name><surname>Kuang</surname><given-names>Q</given-names></name><etal>et al</etal></person-group><article-title>Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: A meta-analysis in Caucasians</article-title><source>Pharmacogenomics J</source><volume>14</volume><fpage>120</fpage>â<lpage>129</lpage><year>2014</year><pub-id pub-id-type="pmid">23529007</pub-id></mixed-citation>
              </ref>
              <ref id="b31">
                <label>31.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bardia</surname><given-names>A</given-names></name><name><surname>Messersmith</surname><given-names>W</given-names></name><name><surname>Kio</surname><given-names>E</given-names></name><etal>et al</etal></person-group><article-title>Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: Final safety and efficacy results from the phase I/II IMMU-132-01 basket trial</article-title><source>Ann Oncol</source><volume>32</volume><fpage>746</fpage>â<lpage>756</lpage><year>2021</year><pub-id pub-id-type="pmid">33741442</pub-id></mixed-citation>
              </ref>
              <ref id="b32">
                <label>32.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dhawan</surname>
                      <given-names>MS</given-names>
                    </name>
                    <name>
                      <surname>Rahimi</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Karipineni</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Phase I study of rucaparib and irinotecan in advanced solid tumors with homologous recombination deficiency (HRD) mutations</article-title>
                  <source>J Clin Oncol</source>
                  <volume>38</volume>
                  <year>2020</year>
                  <issue>15 suppl</issue>
                  <comment>abstr 3513</comment>
                </mixed-citation>
              </ref>
              <ref id="b33">
                <label>33.</label>
                <mixed-citation publication-type="webpage">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Leo</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Johannes</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>Discovery and first structural disclosure of AZD5305: A next generation, highly selective PARP1 inhibitor and trapper</article-title>
                  <comment>Presented at the Virtual American Association for Cancer Research annual meeting, April 10-15, 2021 (abstr ND05). <ext-link xlink:href="https://www.abstractsonline.com/pp8/#!/9325/presentation/874" ext-link-type="uri">https://www.abstractsonline.com/pp8/#!/9325/presentation/874</ext-link></comment>
                </mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
